» Articles » PMID: 30854468

Accumulation of Genetic and Epigenetic Alterations in Normal Cells and Cancer Risk

Overview
Publisher Springer Nature
Specialty Oncology
Date 2019 Mar 12
PMID 30854468
Citations 120
Authors
Affiliations
Soon will be listed here.
Abstract

Cancers develop due to the accumulation of genetic and epigenetic alterations. Genetic alterations are induced by aging, mutagenic chemicals, ultraviolet light, and other factors; whereas, epigenetic alterations are mainly by aging and chronic inflammation. The accumulation and patterns of alterations in normal cells reflect our past exposure levels and life history. Most accumulated alterations are considered as passengers, but their accumulation is correlated with cancer drivers. This has been shown for aberrant DNA methylation but has only been speculated for genetic alterations. However, recent technological advancements have enabled measurement of rare point mutations, and studies have shown that their accumulation levels are indeed correlated with cancer risk. When the accumulation levels of aberrant DNA methylation and point mutations are combined, risk prediction becomes even more accurate. When high levels of alterations accumulate, the tissue has a high risk of developing cancer or even multiple cancers and is considered as a "cancerization field", with or without expansion of physiological patches of clonal cells. In this review, we describe the formation of a cancerization field and how we can apply its detection in precision cancer risk diagnosis.

Citing Articles

Cancer gene identification through integrating causal prompting large language model with omics data-driven causal inference.

Zeng H, Yin C, Chai C, Wang Y, Dai Q, Sun H Brief Bioinform. 2025; 26(2).

PMID: 40072848 PMC: 11899576. DOI: 10.1093/bib/bbaf113.


Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy.

Megdiche Y, Salerno-Goncalves R Front Immunol. 2025; 16:1547213.

PMID: 40040700 PMC: 11876029. DOI: 10.3389/fimmu.2025.1547213.


Deciphering the oncogenic influence of : Implications of matrix metalloproteinase activation.

Nambiar J, Venugopal M, Shaji S, Bose C, Rajeev A, Kalliadan S Heliyon. 2025; 11(4):e42538.

PMID: 40028520 PMC: 11870157. DOI: 10.1016/j.heliyon.2025.e42538.


A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer.

Mahdi Khamaneh A, Jafari-Gharabaghlou D, Ansarin K, Pazooki P, Akbarpour Z, Naghili B Oncol Rev. 2025; 19:1516409.

PMID: 40017494 PMC: 11861078. DOI: 10.3389/or.2025.1516409.


Retinol-Binding Protein 4 as a Biomarker in Cancer: Insights from a Pan-Cancer Analysis of Expression, Immune Infiltration, and Methylation.

Zhao J, Liu Y, Zhou L, Liu Y Genes (Basel). 2025; 16(2).

PMID: 40004479 PMC: 11855459. DOI: 10.3390/genes16020150.


References
1.
Costello J, Fruhwald M, Smiraglia D, Rush L, Robertson G, Gao X . Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000; 24(2):132-8. DOI: 10.1038/72785. View

2.
El-Omar E, Carrington M, Chow W, McColl K, Bream J, Young H . Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000; 404(6776):398-402. DOI: 10.1038/35006081. View

3.
Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S . Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis--A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from.... Hepatology. 2000; 32(5):970-9. DOI: 10.1053/jhep.2000.19797. View

4.
Nohmi T, Suzuki T, Masumura K . Recent advances in the protocols of transgenic mouse mutation assays. Mutat Res. 2000; 455(1-2):191-215. DOI: 10.1016/s0027-5107(00)00077-4. View

5.
Issa J, Ahuja N, Toyota M, Bronner M, Brentnall T . Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001; 61(9):3573-7. View